Medium impact
Faslodex (fulvestrant)
Humana·Effective Nov 1, 2025
Humana Ohio Medicaid implemented a new prior authorization policy for Faslodex (fulvestrant) effective November 1, 2025, for HR-positive, HER2-negative advanced breast cancer. The policy establishes specific approval criteria for monotherapy and combination therapy with CDK 4/6 inhibitors, requiring documentation of menopausal status, prior endocrine therapy history, and disease progression details.